| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
United Kingdom Pharmaceuticals and Healthcare Report Q4 2009
Market |
Healthcare and Medical |
Report Type |
Market Research |
Country |
United Kingdom |
Published |
8 October 2009 |
Number of Pages |
97 |
Download |
|
Immediate |
|
Publisher |
Business Monitor International |
UK Pharmaceuticals: the generics segment is forecast to account for as much as one-third of the market by value in 2013
In BMI’s Business Environment Ratings (BER) for Q409, the UK improved its position by one place, and is now ranked 5th of the 9 Western European markets surveyed. However, while the UK is one of the most developed pharmaceutical markets in the world, pressing economic and political issues – as well as its strict pricing and reimbursement regimes and the upcoming patent cliff – are conspiring to reduce the market’s rate of development in the coming years. In the 2008-2013 period, we forecast a compound annual growth rate (CAGR) of just 0.49 % in local currency terms, with the market value at consumer prices growing from GPB18.8bn (US$34.9bn) to GPB19.3bn (US$32.7bn).
However, although the generics segment is forecast to account for as much as one-third of the market by value in 2013, foreign companies continue to invest in the UK’s pharmaceutical research and development (R&D). In July 2009, Belgian UCB Pharma inaugurated its new GBP25mn (US$37mn) biologics research facility in the UK, which will specialise in the development of therapeutic antibodies. Over the course of 2008, the company ploughed some GBP200mn (US$370mn) into local R&D, confirming its status as the fourth-largest pharmaceutical industry investor in the country. Similarly, Spanish company Almirall Prodesfarma opened a new headquarters in the UK which will serve both the British and Irish markets. Around the same time, the Office for Life Sciences (OLS) – focused on the improvement of operating environment for the pharmaceutical industry – was working on a proposal that aims to allow innovative drugmakers to bypass the National Institute of Clinical Excellence (NICE) via a fast-track procedure. The products would be sold to the National Health Service (NHS) at a higher price, with NICE appraising their cost-effectiveness after a period of three years.
The Association of the British Pharmaceutical Industry (ABPI) has estimated that new medicines – defined as those launched in the last five years – account for a lower proportion of the UK’s total pharmaceutical market than in other developed countries. An additional issue is that of recommendations made by NICE – the medicine advisory agency – not being legally binding, but having a strong influence on the reimbursement environment in the UK. In the meantime, in a bid to tackle the growing care problem as the population ages, the British government proposed a reform of the social care funding system in England. One of the three options laid out by the government is the creation of a compulsory national insurance scheme that would provide care for all elderly citizens. The other options include a partnership approach whereby all citizens would be entitled to a percentage of their costs being paid by the state. The poorest people would qualify for free care and the less well-off would qualify for more government help. However, some people with high care costs would have to raise their own funds via their savings or the sale of their assets. The additional costs could be covered by private insurance, or a voluntary state-backed insurance scheme.
Last Viewed
United Kingdom Pharmaceuticals and Healthcare Report Q4 2009Pinheiro Neto Advogados - Alternative Energy - Advisory Profile
Riverstone Holdings LLC - Clean Technology - Investment Profile
DaimlerChrysler AG - 2009 Fortune Global 500 Company Snapshot
Lotte Chilsung Beverage Co., Ltd. - Financial Analysis Review
Healthcare and Medical Company Profiles
Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
News
Genium Bionic Prosthetic System Represents the First Intuitive Knee
AdCare continues nursing facilities acquisitions strategy
AdCare Purchases US$27.3Mn Nursing Facilities in Arkansas to Drive Strong Revenue Growth
Micromet to Develop Blinatumomab with the National Cancer Institute
AstraZeneca to Develop Targacept’s Product Candidate AZD1446 as a Treatment for Alzheimer’s
Market Insights
Currently there are no Market Insights in this sector.
